178 related articles for article (PubMed ID: 27758888)
1. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
[TBL] [Abstract][Full Text] [Related]
2. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
3. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Ingle JN; Kalari KR; Momozawa Y; Kubo M; Furukawa Y; Shepherd LE; Ellis MJ; Goss PE; Barman P; Carlson EE; Sinnwell JP; Tang X; Goetz MP; Chen BE; Cairns J; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2019 Oct; 29(8):183-191. PubMed ID: 31211741
[TBL] [Abstract][Full Text] [Related]
4. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in lncRNA
Yang H; Sun Q; Chong F; Jiang X; Wang Y; Xu K; Zou Y; Xu L; Song C
Aging (Albany NY); 2021 Nov; 13(21):24360-24378. PubMed ID: 34762068
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
10. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
11. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
[TBL] [Abstract][Full Text] [Related]
13. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Wang L; Ellsworth KA; Moon I; Pelleymounter LL; Eckloff BW; Martin YN; Fridley BL; Jenkins GD; Batzler A; Suman VJ; Ravi S; Dixon JM; Miller WR; Wieben ED; Buzdar A; Weinshilboum RM; Ingle JN
Cancer Res; 2010 Jan; 70(1):319-28. PubMed ID: 20048079
[TBL] [Abstract][Full Text] [Related]
14. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Liu M; Ingle JN; Fridley BL; Buzdar AU; Robson ME; Kubo M; Wang L; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Goetz MP; Northfelt DW; Perez EA; Williard CV; Schaid DJ; Nakamura Y; Weinshilboum RM
Mol Endocrinol; 2013 Apr; 27(4):657-70. PubMed ID: 23518928
[TBL] [Abstract][Full Text] [Related]
15. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
18. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
